AVDL Logo

Avadel Pharmaceuticals plc (AVDL) 

NASDAQ
Market Cap
$1.12B
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
283 of 774
Rank in Industry
12 of 47

Largest Insider Buys in Sector

AVDL Stock Price History Chart

AVDL Stock Performance

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Insider Activity of Avadel Pharmaceuticals plc

Over the last 12 months, insiders at Avadel Pharmaceuticals plc have bought $29,000 and sold $1.09M worth of Avadel Pharmaceuticals plc stock.

On average, over the past 5 years, insiders at Avadel Pharmaceuticals plc have bought $784,810 and sold $514,858 worth of stock each year.

Highest buying activity among insiders over the last 12 months: MCHUGH THOMAS S (Chief Financial Officer) — $29,000.

The last purchase of 2,000 shares for transaction amount of $29,000 was made by MCHUGH THOMAS S (Chief Financial Officer) on 2024‑01‑16.

List of Insider Buy and Sell Transactions, Avadel Pharmaceuticals plc

2024-01-16PurchaseChief Financial Officer
2,000
0.0021%
$14.50$29,000+4.66%
2023-12-28Saledirector
75,000
0.0802%
$14.53$1.09M+5.96%
2023-08-14PurchaseChief Financial Officer
2,000
0.0027%
$14.45$28,900+3.32%
2023-08-11Saledirector
28,975
0.0388%
$14.93$432,614-1.05%
2023-08-10PurchaseChief Executive Officer
10,000
0.0128%
$13.20$131,997+7.26%
2023-08-10Purchasedirector
14,000
0.0182%
$13.40$187,600+7.26%
2023-05-18Purchasedirector
13,000
0.0207%
$13.93$181,100+2.60%
2023-05-09Purchasedirector
2,500
0.0038%
$14.76$36,900-6.72%
2022-12-23Purchasedirector
2,000
0.0033%
$7.20$14,405+61.03%
2022-11-29PurchaseChief Financial Officer
5,000
0.008%
$7.80$39,000+36.61%
2022-11-22Purchasedirector
20,000
0.0314%
$7.80$156,050+32.02%
2022-06-01Purchase
45,000
0.068%
$2.14$96,300+191.25%
2022-05-31Purchase
20,000
0.0349%
$2.27$45,496+216.29%
2022-05-31Purchasedirector
45,000
0.0738%
$2.14$96,300+216.29%
2022-05-27PurchaseChief Executive Officer
50,000
0.0694%
$2.05$102,500+179.00%
2022-05-27Purchase
15,000
0.0249%
$2.45$36,747+179.00%
2022-05-27Purchase
50,000
0.0573%
$1.69$84,500+179.00%
2022-05-27PurchaseChief Financial Officer
50,000
0.0724%
$2.14$106,895+179.00%
2022-05-27Purchase
10,000
0.0108%
$1.60$16,000+179.00%
2020-09-18PurchaseChief Financial Officer
4,000
0.007%
$6.00$24,000+28.91%

Insider Historical Profitability

21.84%
MCHUGH THOMAS SChief Financial Officer
80500
0.0835%
$11.6670+48.83%
McCamish Mark Anthonydirector
67025
0.0696%
$11.6622+28.91%
STAPLETON CRAIG Rdirector
323413
0.3356%
$11.66121<0.0001%
ANDERSON MICHAEL SChief Executive Officer
248953
0.2584%
$11.66111<0.0001%
Ende Eric Jdirector
167900
0.1742%
$11.6690+59%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Janus Henderson$218.18M13.4412.92M+16.09%+$30.24M0.11
RTW Investments, LP$148.61M9.158.8M+26.64%+$31.26M2.23
Polar Capital$114.07M7.036.75M+0.03%+$31,922.100.63
Vivo Capital$67.09M4.133.97M-3.04%-$2.1M5.84
Braidwell Lp$45.07M2.782.67MNew+$45.07M2.55
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.